Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency
M E Conley, A Lavoie, C Briggs, P Brown, C Guerra, J M Puck, M E Conley, A Lavoie, C Briggs, P Brown, C Guerra, J M Puck
Abstract
X chromosome-linked severe combined immunodeficiency (XSCID) is characterized by markedly reduced numbers of T cells, the absence of proliferative responses to mitogens, and hypogammaglobulinemia but normal or elevated numbers of B cells. To determine if the failure of the B cells to produce immunoglobulin might be due to expression of the XSCID gene defect in B-lineage cells as well as T cells, we analyzed patterns of X chromosome inactivation in B cells from nine obligate carriers of this disorder. A series of somatic cell hybrids that selectively retained the active X chromosome was produced from Epstein-Barr virus-stimulated B cells from each woman. To distinguish between the two X chromosomes, the hybrids from each woman were analyzed using an X-linked restriction fragment length polymorphism for which the woman in question was heterozygous. In all obligate carriers of XSCID, the B-cell hybrids demonstrated preferential use of a single X chromosome, the nonmutant X, as the active X. To determine if the small number of B-cell hybrids that contained the mutant X were derived from an immature subset of B cells, lymphocytes from three carriers were separated into surface IgM positive and surface IgM negative B cells prior to exposure to Epstein-Barr virus and production of B-cell hybrids. The results demonstrated normal random X chromosome inactivation in B-cell hybrids derived from the less mature surface IgM positive B cells. In contrast, the pattern of X chromosome inactivation in the surface IgM negative B cells, which had undergone further replication and differentiation, was significantly nonrandom in all three experiments [logarithm of odds (lod) score greater than 3.0]. These results suggest that the XSCID gene product has a direct effect on B cells as well as T cells and is required during B-cell maturation.
References
- Proc Natl Acad Sci U S A. 1970 Jan;65(1):214-8
- J Clin Invest. 1987 May;79(5):1395-400
- J Exp Med. 1973 Dec 1;138(6):1365-78
- N Engl J Med. 1974 Jul 4;291(1):26-35
- Clin Immunol Immunopathol. 1975 Mar;3(4):514-24
- Proc Soc Exp Biol Med. 1975 Feb;148(2):501-4
- J Exp Med. 1975 Apr 1;141(4):788-803
- Lancet. 1975 Dec 13;2(7946):1179-83
- J Clin Invest. 1976 Jul;58(1):130-6
- Clin Exp Immunol. 1976 Oct;26(1):1-10
- J Pediatr. 1978 Sep;93(3):404-11
- Infect Immun. 1979 Oct;26(1):225-31
- J Clin Invest. 1980 Sep;66(3):543-50
- J Immunol. 1980 Oct;125(4):1686-93
- Proc Natl Acad Sci U S A. 1981 Aug;78(8):5066-70
- J Exp Med. 1982 Mar 1;155(3):903-13
- J Exp Med. 1982 Mar 1;155(3):924-36
- Adv Immunol. 1982;33:1-71
- J Immunol. 1983 Apr;130(4):1640-5
- Clin Immunol Immunopathol. 1983 Mar;26(3):390-7
- Mol Cell Biol. 1983 Jun;3(6):1086-96
- J Exp Med. 1983 Aug 1;158(2):616-22
- J Exp Med. 1983 Sep 1;158(3):920-31
- Birth Defects Orig Artic Ser. 1983;19(3):65-72
- Birth Defects Orig Artic Ser. 1983;19(3):73-81
- J Exp Med. 1984 Jan 1;159(1):208-20
- Blood. 1984 Apr;63(4):912-6
- Nature. 1984 May 24-30;309(5966):369-72
- J Exp Med. 1984 Sep 1;160(3):711-23
- J Immunol. 1984 Nov;133(5):2312-6
- J Immunol. 1985 May;134(5):3070-4
- N Engl J Med. 1985 May 2;312(18):1151-9
- J Immunol. 1985 Aug;135(2):959-64
- J Clin Immunol. 1985 Nov;5(6):370-6
- J Immunol. 1986 Apr 1;136(7):2398-407
- N Engl J Med. 1986 Aug 28;315(9):564-7
- J Immunol. 1987 Mar 1;138(5):1403-7
- J Exp Med. 1987 Apr 1;165(4):949-58
- Eur J Immunol. 1973 Feb;3(2):117-8
Source: PubMed